NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Brenus Pharma

Brenus Pharma

Private
LyonHealthcare & Life Scienceshttps://brenus-pharma.com/

Last Round

Series A

Extension

Jul 20, 2026

Total Funding Raised

$34.87M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Brenus Pharma is a clinical-stage biotechnology company that develops allogeneic cancer vaccines using its proprietary 'Stimulated-Tumor-(ghost)-Cells' (STC) platform to educate the immune system to target and destroy cancer cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapycancer immunotherapycancer vaccineSTCsolid tumorsstimulated tumor cellsbiotechnologyoncology biotechtumor resistancecolorectal cancerdrug discoveryclinical trialsprecision medicineproteogenomic profilingtherapeutic assets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Brenus Pharma Comps

Public and private peers based on sector, stage, and business model.

Brenus Pharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Brenus Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJul 20, 2026
Series ASep 18, 2024
GrantJan 22, 2024
SeedMar 17, 2022

Key People

Founding team and executive leadership

Paul Bravetti

Chief Executive Officer

Executive Team

Aymeric Bordet

Chief Financial Officer

Executive Team

Brenus Pharma Investors

Notable investors and investment history

Brenus Pharma investors
InvestorRounds
NoshaqSeries A Extension, Series A
InvestsudSeries A
BpifranceGrant, Seed
KreaxiSeries A
Financière Spin-off LuxembourgeoiseSeries A
French Ministry of the Economy, Finance and Industrial and Digital SovereigntyGrant
AngelorSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 22, 2026

    Grew 19% QoQ, from 21 to 25 employees.

  • Apr 17, 2026

    Monthly visitors grew 40% MoM.

Brenus Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Brenus Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Brenus Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersLyon
Employee Range28
Year Founded2014
Last FundingJul 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.